Rytary Shortage Update: What Patients Need to Know in 2026

If you take Rytary for Parkinson's disease and you're worried about supply — you're right to be paying attention. While Rytary itself is not listed on the FDA drug shortage database or the ASHP shortage list as of 2026, the broader carbidopa-levodopa landscape is complicated, and access to Rytary at retail pharmacies remains challenging for many patients.

This article gives you the most current picture of Rytary's availability, explains the context of what's happening in the Parkinson's medication supply chain, and tells you exactly what you can do to protect your access to medication.

Is Rytary in Shortage in 2026?

No — Rytary (carbidopa and levodopa extended-release capsules, made by Amneal Pharmaceuticals) is not on the FDA's current drug shortage list or the ASHP shortage database as of early 2026. The medication continues to be manufactured and is technically available.

However — and this is important — 'not in shortage' does not mean 'easy to find at your local pharmacy.' Rytary is a high-cost brand-name specialty medication that most retail pharmacies do not routinely stock. Patients consistently report having to call multiple pharmacies, wait several days, or travel further than usual to fill their prescription.

The Real Crisis: Generic Carbidopa-Levodopa ER IS in Shortage

While Rytary brand capsules are not in shortage, generic carbidopa-levodopa extended-release tablets are actively listed as in shortage by the ASHP as of 2026. This is the more affordable formulation that many Parkinson's patients use. Here's what's happened:

Accord Healthcare discontinued the 25/100 mg ER tablet entirely. Only the 50/200 mg strength remains available from Accord.

Sun Pharma discontinued the 25/250 mg orally disintegrating tablet (ODT), affecting patients who need this formulation due to swallowing difficulties.

Only a small number of manufacturers still produce ER formulations, making supply vulnerable to any disruption.

This shortage affects patients who either can't afford Rytary or whose insurance won't cover it. Some patients on generic ER are being pushed toward Rytary as a result, which can create localized demand spikes.

How the Generic ER Shortage Affects Rytary Patients

You might wonder: if I'm already taking Rytary, why does the generic shortage matter to me? Here's why:

When patients are switched from generic ER to Rytary due to the shortage, demand at the few pharmacies that carry Rytary can increase unexpectedly.

If your insurance plan switches formularies and no longer covers Rytary, you may be moved toward generic ER — which is now harder to find.

The overall instability in the carbidopa-levodopa supply chain means it pays to stay proactive regardless of which formulation you take.

Cost Landscape in 2026

Cost is a significant part of the access challenge for Rytary. Here's what patients are paying in 2026:

Rytary (brand ER capsules): $800–$1,500/month without insurance; ~$330–$480 for 90 capsules with SingleCare or similar coupon.

Generic carbidopa-levodopa ER tablets: $50–$80 for 30-day supply retail; as low as $29 with GoodRx or SingleCare.

Generic carbidopa-levodopa IR (immediate release): As low as $9/month with a coupon — widely available.

Amneal Pharmaceuticals (maker of Rytary) offers a savings card through PhilRx for commercially insured patients that can reduce copays to $0–$20 per month. This program does not apply to Medicare or Medicaid patients. See our full guide on how to save money on Rytary for more options.

What Patients Should Do Right Now

Even though Rytary is not in a formal shortage, supply access remains a real challenge. Here's what you should do:

Refill early. Start searching for your next fill 7–10 days before you run out.

Use medfinder to check local pharmacy stock without calling each one yourself.

Know your alternatives. Ask your neurologist what formulation they'd prescribe if Rytary becomes unavailable in your area.

Enroll in the savings program. If you're commercially insured, the Amneal/PhilRx savings card can dramatically reduce your cost and make mail-order or specialty pharmacy more accessible.

Never stop abruptly. Sudden discontinuation of Rytary can cause a severe withdrawal syndrome. Always contact your neurologist before stopping or significantly reducing your dose.